| Lastest Insider Transactions Of AN2 Therapeutics, Inc. ( ANTX ) |
| Symbol | Company Name | Insider Name | Title | Date | Transation | Share | Price | Amount | File Date |
| ANTX | AN2 Therapeutics, Inc. | Readnour Robin Shane | Directior | 2026-09-03 | Sell | 16,119 | 6.04 | 97,323 | 2026-09-08 19:42:53 |
| ANTX | AN2 Therapeutics, Inc. | Williams Sarah Joanne | Principal Accounting Officer | 2026-09-01 | Sell | 272 | 5.53 | 1,504 | 2026-09-04 16:25:33 |
| ANTX | AN2 Therapeutics, Inc. | FitzPatrick Margaret M | Directior | 2026-09-01 | Buy | 2,098 | 5.53 | 11,602 | 2026-09-02 18:43:59 |
| ANTX | AN2 Therapeutics, Inc. | Readnour Robin Shane | Directior | 2026-08-17 | Sell | 35,402 | 6.01 | 212,702 | 2026-08-19 17:58:27 |
| ANTX | AN2 Therapeutics, Inc. | Eizen Joshua M | See Remarks | 2026-07-08 | Sell | 5,945 | 4.17 | 24,803 | 2026-07-10 18:15:57 |
| ANTX | AN2 Therapeutics, Inc. | Williams Sarah Joanne | Principal Accounting Officer | 2026-05-29 | Sell | 265 | 4.43 | 1,174 | 2026-06-02 16:31:36 |
| ANTX | AN2 Therapeutics, Inc. | Williams Sarah Joanne | Principal Accounting Officer | 2026-03-03 | Sell | 327 | 1.06 | 347 | 2026-03-05 18:55:23 |
| ANTX | AN2 Therapeutics, Inc. | Day Lucy | Chief Financial Officer | 2026-01-05 | Sell | 8,807 | 1.01 | 8,883 | 2026-01-07 20:15:21 |
| ANTX | AN2 Therapeutics, Inc. | Day Lucy | Chief Financial Officer | 2026-01-05 | Sell | 8,807 | 1.01 | 8,883 | 2026-01-07 20:15:21 |
| ANTX | AN2 Therapeutics, Inc. | Prior Stephen David | Chief Strategy Officer | 2026-01-05 | Sell | 6,462 | 1.01 | 6,507 | 2026-01-07 20:15:13 |
| ANTX | AN2 Therapeutics, Inc. | Chanda Sanjay | Chief Development Officer | 2026-01-05 | Sell | 9,251 | 1.01 | 9,332 | 2026-01-07 20:13:25 |
| ANTX | AN2 Therapeutics, Inc. | Eizen Joshua M | See Remarks | 2026-01-05 | Sell | 24,854 | 1.00 | 24,962 | 2026-01-07 20:12:16 |
| ANTX | AN2 Therapeutics, Inc. | Eizen Joshua M | See Remarks | 2026-01-05 | Sell | 24,854 | 1.00 | 24,962 | 2026-01-07 20:12:16 |
| ANTX | AN2 Therapeutics, Inc. | Eizen Joshua M | See Remarks | 2025-11-04 | Sell | 2,819 | 1.14 | 3,214 | 2025-11-06 18:12:08 |
| ANTX | AN2 Therapeutics, Inc. | Prior Stephen David | Chief Strategy Officer | 2025-11-04 | Sell | 765 | 1.14 | 872 | 2025-11-06 18:11:32 |
| ANTX | AN2 Therapeutics, Inc. | Leonard Braden Michael | 10% Owner | 2025-06-12 | Sell | 200,000 | 1.09 | 218,000 | 2025-06-16 15:40:59 |
| ANTX | AN2 Therapeutics, Inc. | Easom Eric | Chief Executive Officer | 2025-06-02 | Buy | 10,000 | 1.07 | 10,665 | 2025-06-03 16:46:15 |
| ANTX | AN2 Therapeutics, Inc. | Leonard Braden Michael | 10% Owner | 2025-05-28 | Sell | 2,532,000 | 1.13 | 2,872,477 | 2025-05-30 17:40:38 |
| ANTX | AN2 Therapeutics, Inc. | FitzPatrick Margaret M | Directior | 2025-05-28 | Buy | 8,610 | 1.18 | 10,133 | 2025-05-29 16:17:48 |
| ANTX | AN2 Therapeutics, Inc. | Day Lucy | Chief Financial Officer | 2025-01-03 | Sell | 2,957 | 1.34 | 3,965 | 2025-01-07 20:02:51 |
| ANTX | AN2 Therapeutics, Inc. | Chanda Sanjay | Chief Development Officer | 2025-01-03 | Sell | 2,957 | 1.34 | 3,965 | 2025-01-07 20:00:32 |
| ANTX | AN2 Therapeutics, Inc. | Prior Stephen David | Chief Strategy Officer | 2025-01-03 | Sell | 2,029 | 1.34 | 2,721 | 2025-01-07 19:57:18 |
| ANTX | AN2 Therapeutics, Inc. | Eizen Joshua M | See Remarks | 2025-01-03 | Sell | 9,663 | 1.34 | 12,958 | 2025-01-07 19:57:14 |
| ANTX | AN2 Therapeutics, Inc. | Readnour Robin Shane | Directior | 2024-12-06 | Buy | 60,000 | 1.45 | 86,708 | 2024-12-10 20:46:19 |
| ANTX | AN2 Therapeutics, Inc. | Readnour Robin Shane | Directior | 2024-11-26 | Buy | 75,000 | 1.41 | 105,685 | 2024-11-27 19:07:58 |
| ANTX | AN2 Therapeutics, Inc. | Zakrzewski Joseph S | Directior | 2024-11-27 | Buy | 2,000 | 1.40 | 2,800 | 2024-11-27 16:16:41 |
| ANTX | AN2 Therapeutics, Inc. | Readnour Robin Shane | Directior | 2024-11-19 | Buy | 200,000 | 1.07 | 213,128 | 2024-11-21 18:00:10 |
| ANTX | AN2 Therapeutics, Inc. | Zakrzewski Joseph S | Directior | 2024-11-18 | Buy | 25,000 | 1.00 | 25,046 | 2024-11-20 16:11:58 |
| ANTX | AN2 Therapeutics, Inc. | Easom Eric | Chief Executive Officer | 2024-11-18 | Buy | 50,000 | 1.00 | 49,970 | 2024-11-18 20:51:42 |
| ANTX | AN2 Therapeutics, Inc. | Leonard Braden Michael | 10% Owner | 2024-08-14 | Buy | 1,500,000 | 1.04 | 1,560,000 | 2024-08-14 20:24:00 |
| ANTX | AN2 Therapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | 2024-08-09 | Sell | 3,525,094 | 1.08 | 3,807,102 | 2024-08-13 17:03:34 |
| ANTX | AN2 Therapeutics, Inc. | Zakrzewski Joseph S | Directior | 2024-01-18 | Sell | 100,000 | 19.11 | 1,911,410 | 2024-01-19 19:32:12 |
| ANTX | AN2 Therapeutics, Inc. | Aziz Kabeer | Directior | 2024-01-16 | Sell | 100,000 | 19.65 | 1,965,000 | 2024-01-18 18:19:41 |
| ANTX | AN2 Therapeutics, Inc. | Adjuvant Global Health Technology Fund, L.P. | 10% Owner | 2024-01-16 | Sell | 100,000 | 19.65 | 1,965,000 | 2024-01-18 18:18:45 |
| ANTX | AN2 Therapeutics, Inc. | Readnour Robin Shane | Directior | 2024-01-12 | Sell | 1,425 | 21.91 | 31,229 | 2024-01-17 17:03:32 |
| ANTX | AN2 Therapeutics, Inc. | Readnour Robin Shane | Directior | 2024-01-10 | Sell | 3,669 | 21.93 | 80,443 | 2024-01-12 17:08:10 |
| ANTX | AN2 Therapeutics, Inc. | Krause Kevin Michael | Chief Strategy Officer | 2024-01-09 | Sell | 7,417 | 20.14 | 149,367 | 2024-01-11 19:59:41 |
| ANTX | AN2 Therapeutics, Inc. | Krause Kevin Michael | Chief Strategy Officer | 2024-01-09 | Option Exercise | 7,417 | 4.59 | 34,015 | 2024-01-11 19:59:41 |
| ANTX | AN2 Therapeutics, Inc. | Krause Kevin Michael | Chief Strategy Officer | 2024-01-02 | Sell | 2,583 | 20.12 | 51,967 | 2024-01-04 18:06:42 |
| ANTX | AN2 Therapeutics, Inc. | Krause Kevin Michael | Chief Strategy Officer | 2024-01-02 | Option Exercise | 2,583 | 0.42 | 1,085 | 2024-01-04 18:06:42 |
| ANTX | AN2 Therapeutics, Inc. | Easom Eric | Chief Executive Officer | 2024-01-02 | Sell | 2,777 | 20.09 | 55,802 | 2024-01-04 18:05:51 |
| ANTX | AN2 Therapeutics, Inc. | Adjuvant Global Health Technology Fund, L.P. | 10% Owner | 2023-11-14 | Sell | 1,810 | 16.15 | 29,224 | 2023-11-16 18:59:54 |
| ANTX | AN2 Therapeutics, Inc. | Aziz Kabeer | Directior 10% Owner | 2023-11-14 | Sell | 1,810 | 16.15 | 29,224 | 2023-11-16 18:57:17 |
| ANTX | AN2 Therapeutics, Inc. | Aziz Kabeer | Directior 10% Owner | 2023-09-29 | Sell | 104,773 | 16.27 | 1,704,513 | 2023-10-03 19:21:18 |
| ANTX | AN2 Therapeutics, Inc. | Adjuvant Global Health Technology Fund, L.P. | 10% Owner | 2023-09-29 | Sell | 104,773 | 16.27 | 1,704,513 | 2023-10-03 19:13:42 |
| ANTX | AN2 Therapeutics, Inc. | Adjuvant Global Health Technology Fund, L.P. | 10% Owner | 2023-09-27 | Sell | 9,357 | 16.11 | 150,708 | 2023-09-29 17:41:08 |
| ANTX | AN2 Therapeutics, Inc. | Aziz Kabeer | Directior 10% Owner | 2023-09-27 | Sell | 9,357 | 16.11 | 150,708 | 2023-09-29 17:40:05 |
| ANTX | AN2 Therapeutics, Inc. | Aziz Kabeer | Directior 10% Owner | 2023-08-23 | Sell | 400 | 16.00 | 6,400 | 2023-09-15 17:40:36 |
| ANTX | AN2 Therapeutics, Inc. | Adjuvant Global Health Technology Fund, L.P. | 10% Owner | 2023-08-23 | Sell | 400 | 16.00 | 6,400 | 2023-09-15 17:17:35 |
| ANTX | AN2 Therapeutics, Inc. | Adjuvant Global Health Technology Fund, L.P. | 10% Owner | 2023-08-23 | Sell | 7,140 | 16.03 | 114,484 | 2023-09-08 16:59:56 |
| ANTX | AN2 Therapeutics, Inc. | Aziz Kabeer | Directior 10% Owner | 2023-08-23 | Sell | 7,140 | 16.03 | 114,484 | 2023-09-08 16:57:59 |
| ANTX | AN2 Therapeutics, Inc. | Adjuvant Global Health Technology Fund, L.P. | 10% Owner | 2023-08-23 | Sell | 400 | 16.00 | 6,400 | 2023-08-25 16:31:35 |
| ANTX | AN2 Therapeutics, Inc. | Aziz Kabeer | Directior 10% Owner | 2023-08-23 | Sell | 400 | 16.00 | 6,400 | 2023-08-25 16:30:49 |
| ANTX | AN2 Therapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | 2023-08-18 | Buy | 1,777,778 | 9.00 | 16,000,002 | 2023-08-22 17:01:31 |
| ANTX | AN2 Therapeutics, Inc. | Easom Eric | Chief Executive Officer | 2023-05-15 | Buy | 10,000 | 5.38 | 53,770 | 2023-05-15 20:01:16 |
